Abstract
With billions of dollars in research and development (R&D) funding continuing to be invested, the novel coronavirus disease 2019 (COVID-19) has become into a singular focus for the scientific community. However, the collective response from the scientific communities have seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise. In this article, we argue for the importance of structural changes to existing research programs for clinical trials in light of the lessons learned from COVID-19.
All Keywords
【초록키워드】 COVID-19, coronavirus disease, Coronavirus disease 2019, clinical trial, clinical trials, research and development, novel coronavirus disease, Novel coronavirus, therapeutic, Research, Scientific community, change, singular, Investment, Return on investment, 【제목키워드】 protocol, Research,
【초록키워드】 COVID-19, coronavirus disease, Coronavirus disease 2019, clinical trial, clinical trials, research and development, novel coronavirus disease, Novel coronavirus, therapeutic, Research, Scientific community, change, singular, Investment, Return on investment, 【제목키워드】 protocol, Research,
{{{ 추상적인 }}}
수십억 달러의 연구 개발(R&D) 자금이 계속 투자되면서 2019년 신종 코로나바이러스 감염증(COVID-19)이 과학계의 단일 초점이 되었습니다. 그러나 과학계의 집단적 반응은 특히 COVID-19에 대한 치료 연구에 대한 투자 수익률이 좋지 않아 임상 시험 기업의 기존 약점과 비효율성을 드러냈습니다. 이 기사에서 우리는 COVID-19에서 배운 교훈에 비추어 임상 시험을 위한 기존 연구 프로그램에 대한 구조적 변화의 중요성을 주장합니다.